WESTBURY, N.Y.--(BUSINESS WIRE)--Vasomedical, Inc. (“Vasomedical”) (OTC: VASO.PK), a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, today announced the third party publication of a seminal study on the positive effects of Enhanced External Counterpulsation (EECP®) therapy in patients with non-insulin dependent abnormal glucose tolerance (AGT), providing what is considered as “novel evidence that EECP has a beneficial effect on peripheral arterial function and glucose tolerance in subjects with AGT.”
